LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Endometrial cancer (EC) cells display altered glucose metabolism, favoring aerobic glycolysis.
• Targeting glucose metabolism presents a potential therapeutic strategy for EC.

Purpose of the Study:

• To investigate the roles of LIN28B, PCAT5, and IGF2BP3 in EC cell glucose metabolism, proliferation, migration, and invasion.
• To elucidate the LIN28B/PCAT5/IGF2BP3 axis in regulating EC malignant behaviors.

Main Methods:

• Analysis of LIN28B, PCAT5, and IGF2BP3 expression in EC cells.
• Investigation of molecular interactions between LIN28B, PCAT5, and IGF2BP3.
• Assessment of the impact of the LIN28B/PCAT5/IGF2BP3 axis on glucose metabolism enzymes (HK2, PKM2) and EC cell behaviors.

Main Results:

• LIN28B stabilizes PCAT5, which in turn stabilizes IGF2BP3 by preventing MKRN2 binding.
• IGF2BP3 promotes aerobic glycolysis, proliferation, migration, and invasion in EC cells by stabilizing HK2 and PKM2.
• The LIN28B/PCAT5/IGF2BP3 axis is crucial for glucose reprogramming and malignant phenotypes in EC cells.

Conclusions:

• The LIN28B/PCAT5/IGF2BP3 axis is a key regulator of glucose metabolism and malignant behavior in endometrial cancer.
• Targeting this axis may provide a novel therapeutic approach for endometrial cancer metabolism.